Gerald Klose1, Ulrich Laufs2, Winfried März3, Eberhard Windler4. 1. Private practice for Internal Medicine, Gastroenterology, Cardiology and Preventional Medicine: Dres. T. Beckenbauer und S. Maierhof and joint practice Dres. K. W. Spieker and I van de Loo, Bremen. 2. Department of Internal Medicine III-Cardiology, Angiology and Intensive Care Medicine, Saarland University Medical Center, Homburg/Saar. 3. Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University Graz; Synlab Academy, Synlab Services GmbH, Mannheim. 4. Preventive Medicine, Department of General and Interventional Cardiology, University Hospital Hamburg-Eppendorf, Hamburg.
Abstract
BACKGROUND: Familial hypercholesterolemia (FH) is a congenital disorder of lipid metabolism characterized by a marked elevation of the plasma concentration of LDL (low-density lipoprotein) cholesterol beginning in childhood and by the early onset of coronary heart disease. It is among the commonest genetic disorders, with an estimated prevalence in Germany of at least 1 per 500 persons. METHOD: Review of pertinent literature retrieved by a selective search. RESULTS: FH is underdiagnosed and undertreated in Germany. It is clinically diagnosed on the basis of an elevated LDL cholesterol concentration (>190 mg/dL [4.9 mmol/L]), a family history of hypercholesterolemia, and early coronary heart disease, or the demonstration of xanthomas. The gold standard of diagnosis is the identification of the underlying genetic defect, which is possible in 80% of cases and enables the identification of affected relatives of the index patient. The recommended goals of treatment, based on the results of observational studies, are to lower the LDL cholesterol concentration by at least 50% or to less than 100 mg/dL (2.6 mmol/L) (for children: <135 mg/dL [3.5 mmol/L]). The target value is lower for patients with clinically overt atherosclerosis (<70 mg/dL [1.8 mmol/L]). Statins, combined with a health-promoting lifestyle, are the treatment of choice. Lipoprotein apheresis is used in very severe cases; its therapeutic effects on clinical endpoints and its side effect profile have not yet been documented in randomized controlled trials. CONCLUSION: Familial hypercholesterolemia is a common disease that can be diagnosed simply and reliably on clinical grounds and by molecular genetic testing. Timely diagnosis and appropriate treatment can lower the risk of atherosclerosis in heterozygous patients to that of the general population.
BACKGROUND:Familial hypercholesterolemia (FH) is a congenital disorder of lipid metabolism characterized by a marked elevation of the plasma concentration of LDL (low-density lipoprotein) cholesterol beginning in childhood and by the early onset of coronary heart disease. It is among the commonest genetic disorders, with an estimated prevalence in Germany of at least 1 per 500 persons. METHOD: Review of pertinent literature retrieved by a selective search. RESULTS:FH is underdiagnosed and undertreated in Germany. It is clinically diagnosed on the basis of an elevated LDL cholesterol concentration (>190 mg/dL [4.9 mmol/L]), a family history of hypercholesterolemia, and early coronary heart disease, or the demonstration of xanthomas. The gold standard of diagnosis is the identification of the underlying genetic defect, which is possible in 80% of cases and enables the identification of affected relatives of the index patient. The recommended goals of treatment, based on the results of observational studies, are to lower the LDL cholesterol concentration by at least 50% or to less than 100 mg/dL (2.6 mmol/L) (for children: <135 mg/dL [3.5 mmol/L]). The target value is lower for patients with clinically overt atherosclerosis (<70 mg/dL [1.8 mmol/L]). Statins, combined with a health-promoting lifestyle, are the treatment of choice. Lipoprotein apheresis is used in very severe cases; its therapeutic effects on clinical endpoints and its side effect profile have not yet been documented in randomized controlled trials. CONCLUSION:Familial hypercholesterolemia is a common disease that can be diagnosed simply and reliably on clinical grounds and by molecular genetic testing. Timely diagnosis and appropriate treatment can lower the risk of atherosclerosis in heterozygous patients to that of the general population.
Authors: Alpo Vuorio; Jaana Kuoppala; Petri T Kovanen; Steve E Humphries; Timo Strandberg; Serena Tonstad; Helena Gylling Journal: Cochrane Database Syst Rev Date: 2010-07-07
Authors: Evan A Stein; Dan Gipe; Jean Bergeron; Daniel Gaudet; Robert Weiss; Robert Dufour; Richard Wu; Robert Pordy Journal: Lancet Date: 2012-05-26 Impact factor: 79.321
Authors: S Moorjani; M Roy; C Gagné; J Davignon; D Brun; M Toussaint; M Lambert; L Campeau; S Blaichman; P Lupien Journal: Arteriosclerosis Date: 1989 Mar-Apr
Authors: Marina Cuchel; Emma A Meagher; Hendrik du Toit Theron; Dirk J Blom; A David Marais; Robert A Hegele; Maurizio R Averna; Cesare R Sirtori; Prediman K Shah; Daniel Gaudet; Claudia Stefanutti; Giovanni B Vigna; Anna M E Du Plessis; Kathleen J Propert; William J Sasiela; LeAnne T Bloedon; Daniel J Rader Journal: Lancet Date: 2012-11-02 Impact factor: 79.321
Authors: K Steyn; Y P Goldberg; M J Kotze; M Steyn; A S Swanepoel; J M Fourie; G A Coetzee; D R Van der Westhuyzen Journal: Hum Genet Date: 1996-10 Impact factor: 4.132
Authors: Laney K Jones; Samuel S Gidding; Terry L Seaton; Anne Goldberg; Christina Gregor; Amy C Sturm; Ross C Brownson; Alanna Kulchak Rahm; Marc S Williams Journal: Res Social Adm Pharm Date: 2019-06-15